世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

世界の遺伝性血管性浮腫治療市場 2018-2022年

Global Hereditary Angioedema Therapeutics Market 2018-2022

IRTNTR23701

 

出版社 出版年月電子版価格 ページ数
TechNavio
テクナビオ
2018年9月US$2,500
シングルユーザライセンス
108

サマリー

この調査レポートは世界の遺伝性血管性浮腫治療市場を分析・予測したTechNavioの市場調査報告書です。

Description

About Hereditary Angioedema Therapeutics
Hereditary angioedema is a rare genetic disease characterized by swelling of various parts of the body. The swelling is mainly observed in the face region and airways. It also leads to abdominal cramping.
Technavio’s analysts forecast the Global Hereditary Angioedema Therapeutics Market to grow at a CAGR of 8.94% during the period 2018-2022.

Covered in this report
The report covers the present scenario and the growth prospects of the hereditary angioedema therapeutics market. To calculate the market size, the report considers the revenue generated from the hereditary angioedema therapeutics.

Technavio's report, hereditary angioedema therapeutics market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

Key vendors
- BioCryst Pharmaceuticals
- Cipla
- CSL
- Pharming Group
- Shire

Market driver
- Increasing prevalence of hereditary angioedema
- For a full, detailed list, view our report
Market challenge
- High cost of treatment
- For a full, detailed list, view our report

Market trend
- Innovative treatment strategies
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2022 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.



目次

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 05: MARKET SIZING
- Market definition
- Market sizing 2017
- Market size and forecast 2017-2022
PART 06: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 07: PIPELINE LANDSCAPE
PART 08: MARKET SEGMENTATION BY PRODUCT
- Segmentation by product
- Comparison by product
- C1 inhibitors - Market size and forecast 2017-2022
- Icatibant - Market size and forecast 2017-2022
- Ecallantide - Market size and forecast 2017-2022
- Others - Market size and forecast 2017-2022
- Market opportunity by product
PART 09: CUSTOMER LANDSCAPE
PART 10: REGIONAL LANDSCAPE
- Geographical segmentation
- Regional comparison
- Americas - Market size and forecast 2017-2022
- EMEA - Market size and forecast 2017-2022
- APAC - Market size and forecast 2017-2022
- Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 13: MARKET TRENDS
- Innovative treatment strategies
- Improved route of administration products
- Development of monoclonal antibody
PART 14: VENDOR LANDSCAPE
- Overview
- Landscape disruption
PART 15: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- BioCryst Pharmaceuticals
- Cipla
- CSL
- Pharming Group
- Shire
PART 16: APPENDIX
- List of abbreviations


Exhibit 01: Parent market
Exhibit 02: Global rare disease market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global - Market size and forecast 2017-2022 ($ mn)
Exhibit 09: Global - Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2017
Exhibit 18: Pipeline landscape by development phase
Exhibit 19: Key clinical trial candidates of hereditary angioedema
Exhibit 20: Product - Market share 2017-2022 (%)
Exhibit 21: Comparison by product
Exhibit 22: C1 inhibitors - Market size and forecast 2017-2022 ($ mn)
Exhibit 23: C1 inhibitors - Year-over-year growth 2018-2022 (%)
Exhibit 24: Icatibant - Market size and forecast 2017-2022 ($ mn)
Exhibit 25: Icatibant - Year-over-year growth 2018-2022 (%)
Exhibit 26: Ecallantide - Market size and forecast 2017-2022 ($ mn)
Exhibit 27: Ecallantide - Year-over-year growth 2018-2022 (%)
Exhibit 28: Others - Market size and forecast 2017-2022 ($ mn)
Exhibit 29: Others - Year-over-year growth 2018-2022 (%)
Exhibit 30: Market opportunity by product
Exhibit 31: Customer landscape
Exhibit 32: Global - Market share by geography 2017-2022 (%)
Exhibit 33: Regional comparison
Exhibit 34: Americas - Market size and forecast 2017-2022 ($ mn)
Exhibit 35: Americas - Year-over-year growth 2018-2022 (%)
Exhibit 36: Top three countries in Americas
Exhibit 37: EMEA - Market size and forecast 2017-2022 ($ mn)
Exhibit 38: EMEA - Year-over-year growth 2018-2022 (%)
Exhibit 39: Top three countries in EMEA
Exhibit 40: APAC - Market size and forecast 2017-2022 ($ mn)
Exhibit 41: APAC - Year-over-year growth 2018-2022 (%)
Exhibit 42: Top three countries in APAC
Exhibit 43: Market opportunity
Exhibit 44: Vendor landscape
Exhibit 45: Landscape disruption
Exhibit 46: Vendors covered
Exhibit 47: Vendor classification
Exhibit 48: Market positioning of vendors
Exhibit 49: BioCryst Pharmaceuticals: Overview
Exhibit 50: BioCryst Pharmaceuticals: Organizational developments
Exhibit 51: BioCryst Pharmaceuticals: Key offerings
Exhibit 52: BioCryst Pharmaceuticals: Key customers
Exhibit 53: Cipla - Overview
Exhibit 54: Cipla - Business segments
Exhibit 55: Cipla - Organizational developments
Exhibit 56: Cipla - Geographic focus
Exhibit 57: Cipla - Segment focus
Exhibit 58: Cipla - Key offerings
Exhibit 59: Cipla - Key customers
Exhibit 60: CSL - Overview
Exhibit 61: CSL - Business segments
Exhibit 62: CSL - Organizational developments
Exhibit 63: CSL - Geographic focus
Exhibit 64: CSL - Segment focus
Exhibit 65: CSL - Key offerings
Exhibit 66: CSL - Key customers
Exhibit 67: Pharming Group - Overview
Exhibit 68: Pharming Group - Business segments
Exhibit 69: Pharming Group - Organizational developments
Exhibit 70: Pharming Group - Geographic focus
Exhibit 71: Pharming Group - Key offerings
Exhibit 72: Pharming Group - Key customers
Exhibit 73: Shire - Overview
Exhibit 74: Shire - Business segments
Exhibit 75: Shire - Organizational developments
Exhibit 76: Shire - Geographic focus
Exhibit 77: Shire - Segment focus
Exhibit 78: Shire - Key offerings
Exhibit 79: Shire - Key customers


-?

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る